Screener
Acadia Pharmaceuticals ACAD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | 14,973 | 13,545 | 15,317 | 22,337 |
| Net income | $31,500 | $26,666 | $35,137 | $45,653 |
| Earnings per share: | ||||
| Basic | $0.18 | $0.16 | $0.21 | $0.27 |
| Diluted | $0.18 | $0.16 | $0.20 | $0.27 |
| Weighted average common shares outstanding: | ||||
| Basic | 171,603 | 167,827 | 171,063 | 167,321 |
| Diluted | 172,851 | 168,681 | 172,890 | 168,219 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's EPS (diluted)?
- Acadia Pharmaceuticals (ACAD) reported EPS (diluted) of $0.18 in Q2 2026.
- How has Acadia Pharmaceuticals's EPS (diluted) changed year-over-year?
- Acadia Pharmaceuticals's EPS (diluted) increased by 12.5% year-over-year, from $0.16 to $0.18.
- What is the long-term trend for Acadia Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's EPS (diluted) has grown at a 21.7% compound annual growth rate (CAGR), from -$1.05 to $2.30.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Acadia Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude